AstraZeneca expanding R&D pipeline in China
In an interview with China Daily, Sharon Barr, executive vice-president of biopharmaceuticals R&D at AstraZeneca, said the company’s presence in Shanghai is absolutely critical to achieving its bold ambition to be a pioneer in science and to create transformative new medicines for patients. She said that China has its vibrant academic collaborative network and the…









